Tag:
Debio 025
Latest Headlines
Latest Headlines
Novartis licenses hep C drug from Debiopharm
Novartis has signed a deal with Switzerland's Debiopharm to develop and market Debio 025 (alisporivir), an antiviral agent for hepatitis C. Debio 025, which is currently in Phase II, is the first in
